>>NCT00438724
Inclusion Criteria:
Couples, in which one partner has been diagnosed with AD and is in the mild stage of the disease
Ages 21 to 90 
Exclusion Criteria:
Severe psychological or physical illness
Unwillingness to participate in all aspects of the study

>>NCT02500784
Inclusion Criteria:
Males and females between the ages of 50-85,
Mild-to-moderate AD (NINCDS/ADRDA criteria for probable AD will be used to establish AD diagnosis)
MMSE 16-26
Exclusion Criteria:
Non-AD dementia or significant neurological disease such as Parkinson's disease, stroke, brain tumor,multiple sclerosis, seizure disorder, focal brain lesion, or head injury with loss of consciousness
Hypothyroidism, congestive heart failure (New York Heart Association Class III or IV), significant extrapyramidal symptoms on neurological examination, serum creatinine >1.3 mg/dl, significant arrhythmias or conduction defect abnormalities on ECG,
Use of another beta2 adrenergic drug within the last 2 months
Residence in a long-term care facility
Evidence of any significant clinical disorder or laboratory finding that renders the person unsuitable for receiving an investigational new drug
Known hypersensitivity or prior exposure to formoterol
Active asthma or family history of asthma

>>NCT01231295
Inclusion Criteria for the group with memory problems:
patient consulting for memory problems
caucasian
memory complaint is validated by a clinical evaluation
cognitive performance is sufficiently well preserved so that a diagnostic of dementia cannot be made (according to the DSM-IV-R and NINCDS-ADRDA criteria) at the time of inclusion
the patient speaks French
presence of an informant
accepts to sign consent Inclusion Criteria for the group without memory problems (reference population):
at least four years of formal education
patient consulting for memory problems
memory problem reported by the patient is not validated by the consultation, nor by the battery of tests specified during screening
presence of an informant
Clinical Dementia Rating (CDR) > 0
accepts to sign consent 
Exclusion Criteria:
Instrumental Activities of Daily Living (IADL): at least two items 1
Anticholinesterasic treatments and/or memantine before study inclusion
major depressive syndrome, according to the Global Depressive Scale
Known neurodegenerative disease or general disease or major physical problems that could interfere with cognitive functioning and testing
Pathology that might lead to death in the short term (evolving cancer, non stable cardiopathy, hepatic, renal or respiratory insufficiency)
contra-indications for MRI, PET or SPECT scans
not affiliated with a social security regimen

>>NCT01743534
Inclusion Criteria:
Men and women of more than 75 years
Patients suffering from insanities of type Alzheimer
Severe stage of the disease
Residents in a Hospital for dependent old persons, with its own dining room
Persons accommodated in the clinical service for more than 30 days
EBS score < 16
Information in the participation of the resident, their legal representative and their family
Patients affiliated to the Social Security
Filled and signed form of participation
Patient having a appointed reliable person or one helping known whose references are indicated in the patient file
Exclusion Criteria:
Patients presenting pathologies being able to interfere with the evaluation
Participating patients in another research for type clinical trial
Undernutrition patients
Patients presenting oral hurts
Protected patient or having nobody helping

>>NCT01524887
Inclusion Criteria:
Males or females of age 50 to 89 years inclusive at the time of screening
Written informed consent obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures
Written informed consent obtained from an able and competent caregiver who is willing to comply with the requirements of the protocol pertaining to him/her, including facilitating the subject's participation in the study
Diagnosis of Probable Alzheimers Disease (AD) according to NINCDS-ADRDA* 1984 criteria National Institute of Neurological and Communicative Disorders and Stroke Alzheimer's Disease and Related Disorders Association)
Dementia of mild to moderate severity (Mini-Mental State Examination MMSE] 16-26 inclusive at the time of screening)
Neuroimaging (computed tomography CT or MRI) performed after symptom onset consistent with AD diagnosis
Willingness to comply with the requirements of the protocol and ability to comply with testing and infusion regimen, including adequate corrected visual acuity and hearing ability
For at least 12 weeks prior to screening, on stable doses of AD medication(s) approved by local regulatory authorities
Subjects must not be on two acetylcholinesterase inhibitors concurrently
Venous access for repeated infusion and phlebotomy
If receiving psychoactive medications (e.g., antidepressants other than monoamine oxidase inhibitors MAOIs] and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc
must be on stable doses for at least 6 weeks prior to screening
For women of childbearing potential, the subject must have a negative pregnancy test at screening and must agree to employ adequate contraceptive measures (e.g., birth control pills/patches, intrauterine device, or diaphragm or condom for male partner] with spermicidal jelly or foam) throughout the course of the study
For subjects with a coronary artery stent, the subject must receive documented medical clearance from an interventional cardiologist stating that the subject is not at increased risk for stent occlusion with immunoglobulin treatment
For subjects with an endovascular stent, the subject must receive documented medical clearance from a vascular surgeon stating that the subject is not at increased risk for thromboembolic events with immunoglobulin treatment 
Main Exclusion Criteria:
Possible AD by NINCDS-ADRDA criteria or non-Alzheimer dementia (e.g.,vascular dementia, dementia with Lewy bodies, frontotemporal dementia, or dementia arising from other diseases or conditions such as Parkinson's disease, vitamin B12 deficiency, thyroid abnormalities)
Current residence in a skilled nursing facility
Contraindication to undergoing MRI (e.g.,pacemaker with the exception of an MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a metal plate)
Clinically significant congestive heart failure (e.g.,New York Heart Association NYHA] Class III/IV symptoms or untreated Class II)
Current atrial fibrillation of unstable angina (angina at rest) or history of myocardial infarction within the 12 months prior to screening
Uncontrolled hypertension defined as systolic blood pressure 160 mm Hg and/or diastolic 100 mm Hg confirmed upon repeated measures
History of thrombosis and/or thromboembolic disease (central or peripheral) within the 12 months prior to screening
Known history of procoagulant abnormalities (e.g.,factor V Leiden, antiphospholipid syndrome, protein S/protein C deficiency, AT III deficiency)
History of intracerebral hemorrhage within the 5 years prior to screening
Evidence on MRI of: greater than 4 microhemorrhages (regardless of their anatomical location or diagnostic characterization as possible" or definite"), a single area of superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, prominent white matter disease with a rating score of 3 on the age-related white matter changes (ARWMC) scale from the European Task Force on ARWMC, or multiple lacunae (defined as more than 2 lacunae that are greater than 0.5 mm in size)
Head trauma with loss of consciousness, contusion, or open head injury within the 12 months prior to screening
Uncontrolled seizure disorder as defined by two or more breakthrough seizures per year despite adequate antiepileptic drug (AED) treatment
Modified Hachinski score 4 at time of screening
Subjects with active malignancy or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment
Active autoimmune or neuro-immunologic disorder
Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)
Poorly controlled diabetes, defined as glycosylated (or glycated) hemoglobin (HbA1c) > 6.5% at screening
Creatinine clearance 50% of normal adjusted for age and gender, as calculated according to the Cockcroft-Gault formula, at the time of screening
Known history of untreated vitamin B12 deficiency within 6 months prior to screening, or clinically significant abnormally low vitamin B12 at the time of screening
Abnormal clinical chemistry panel or hematology panel meeting any one of the following criteria:
Serum alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
Clinically significant anemia that precludes repeated blood sampling or hemoglobin (Hgb) < 10.0 g/dL
Absolute neutrophil count (ANC)  < 1000 cells/L
Known coagulopathy or platelet counts < 100,000 cells/L
Total serum protein > 9 g/dL
Known history of or positive serology at screening for one or more of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) type 1/2 antibody
Immunoglobulin A (IgA) deficiency 8 mg/dL)
Known history of hypersensitivity following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)
Currently receiving or has received: anti-CD20 therapy within 12 months prior to screening, or other immunomodulatory therapies (e.g.m anti-TNF, anti-IL-1, interferon) within 12 weeks prior to screening
The following exceptions are allowed: non-systemic corticosteroids (e.g.,topical, ophthalmic or inhaled glucocorticoids) and low-dose systemic corticosteroids (prednisone 10 mg/day or its equivalent)
Currently receiving or has received intravenous or subcutaneous immunoglobulin treatment within the 2 years prior to screening, or has received immunoglobulin in Baxter Protocol 160701
Currently receiving or has received at any time active immunization aimed at modulating AD progression
Currently receiving or has received within 12 months prior to screening any investigational device, drug or biologic (e.g.,passive immunotherapies with monoclonal or polyclonal antibodies) aimed at modulating AD progression
Subject has been exposed to an investigational product (IP) or investigational device within 12 weeks prior to screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Subject is a family member or employee of the investigator
The subject is nursing or intends to begin nursing during the course of the study
Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (e.g.,blood tests, urine tests, electrocardiogram, chest x-ray), that in medical judgment may impede the subject's participation in the study, pose increased risk to the subject, or confound the results of the study
Currently receiving anti-coagulant agent and/or anti-platelet agent other than acetylsalicylic acid (aka. aspirin)

>>NCT02167256
Inclusion Criteria 
1. NIA-Alzheimer's Association core clinical criteria for probable AD 
2. 18F-Florbetapir scan with evidence of elevated A (based on central review) 
3. Age between 55-85 (inclusive) 
4. MMSE score between 18 and 26 (inclusive) 
5. Stability of permitted medications for 4 weeks
In particular:
Stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 year)
Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screen 
6. Geriatric Depression Scale less than 6 Note: a score 6 on this screening scale may be permissible, if the subject is examined by a site clinician and judged not to be depressed
7. Study partner is available who has frequent contact with the subject (e.g.,average of 10 hours per week or more), and can accompany the subject to most visits to answer questions about the subject 
8. Visual and auditory acuity adequate for neuropsychological testing 
9. Good general health with no disease expected to interfere with the study 
10. Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile) 
11. Modified Hackinski less than or equal to 4 
12. Completed six grades of education or has a good work history 
13. Must speak English or Spanish fluently 
Exclusion Criteria 
1. Any significant neurologic disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities 
2. Screening/baseline MRI scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure 
3. Subjects that have any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker 
4. Major depression, bipolar disorder as described in DSM-IV within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol 
5. History of schizophrenia (DSM V criteria) 
6. History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria) 
7. Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study
8. Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment 
9. Clinically significant abnormalities in B12 or TFTs that might interfere with the study
A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant
10. Residence in skilled nursing facility
11. Use of any excluded medication as described in study protocol 
12. Current or recent participation in any procedures involving radioactive agents, including current, past, or anticipated exposure to radiation in the workplace, such that the total radiation dose exposure to the subject in a given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1
This guideline is an effective dose of 5 rem received per year
13. Neutropenia defined as absolute neutrophils count of < 1,500/microliter 
14. Thrombocytopenia defined as platelet count > 100x103/microliter 
15. For CSF sub-study participants, a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening 
16. Clinically significant abnormalities in screening laboratories, including:
Aspartate aminotransferase (AST) > 1.5 times ULN
Alanine aminotransferase (ALT) > 1.5 times ULN
Total bilirubin > 1.5 times ULN
Serum creatinine > 2.0 times ULN 
17. History of interstitial lung disease 
18. Patients whom the PI deems to be otherwise ineligible

>>NCT01018875
Inclusion Criteria: 
1. Have voluntarily signed an informed consent
2. Subject meets diagnostic criteria criteria for probable AD (Alzheimer's Disease)
3. Female subjects must be postmenopausal for at least 2 years or surgically sterile
4. Male subjects must be surgically sterile, sexually inactive or using a barrier method of birth control
5. Subject has an identified, reliable caregiver
6. Subject has a CT or MRI scan within 36 months prior to randomization
7. With the exception of a diagnosis of mild-to-moderate AD and the presence of stable medical conditions, the subject is generally in good health based on medical history, physical examination, vital signs, clinical lab tests and ECG 
Exclusion Criteria: 
1. Subject is currently taking or has taken a medication for the treatment of AD or dementia with 60 days of Screening visit, or is participating in cognitive therapy for the treatment of AD or dementia
2. Subject uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence
3. Subject has a history of any significant neurologic disease other than AD
4. Subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation
5. Subject has received any investigation product within 6 weeks prior to study drug administration

>>NCT00153010
INCLUSION CRITERIA 
Patients may be included in this study if they meet all of the following criteria: 
1. Male, and female without child bearing potential between 40 and 85 years of age, inclusive
Women who have been postmenopausal for less than 2 years must have a negative pregnancy test at screening
2. Diagnosis of probable mild to moderate Dementia of the Alzheimer's Type as defined by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS ADRDA) guidelines. 
3. Mini-Mental State Examination (MMSE) score of 10-24 and Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scoregeater than 12 at screening
4. Modified Hachinski Scale10 score no greater than 4
5. Central nervous system imaging (CT or MRI scan of brain) compatible with Dementia of the Alzheimer's Type within the past year (also see exclusion criteria)
6. Exhibits reliability and physiologic capability sufficient to comply with all protocol procedures
Patient must be familiar with and fluent in English (i.e. sufficient to complete all study assessments from the language perspective)
7. Patients and/or a legal representative and their caregivers must have given informed consent
The legal representative and caregiver may be the same person
8. Patient must have a reliable caregiver that is in frequent or daily contact with the patient, who will accompany the patient to the office and who will monitor the administration of prescribed medications
The caregiver will be able to communicate in English and be willing to comply with protocol requirements
EXCLUSION CRITERIA 
Patients must be excluded from this study if they meet any of the following criteria: 
1. Secondary disorders inducing dementia such as neurosyphilis, craniocerebral trauma (CT/MRI), hyperthyroidism, or folic acid deficiency
2. History of malignancy within 3 years, except for basal cell carcinoma
3. History or diagnosis of symptomatic and/or unstable/uncontrolled:
Cardiovascular illnesses such as chronic congestive heart failure (with or without edema), arrhythmias, labile hypertension, ischemic heart disease, myocardial infarction (with residual angina), orthopnea, conduction defects (ECG), or other heart disease classified NYHA III or IV
Liver disease such as cirrhosis, hepatitis B, hepatitis C, or primary or metastatic neoplasm
Gastrointestinal disorder such as GI bleeding, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease
Renal disease (primary or secondary) such as chronic renal failure (CLCR 30 mL/min)
Endocrine disease such as diabetes mellitus or hypothyroidism
Neurological disease (other than Dementia of the Alzheimer's Type such as Huntington's disease, Parkinson's disease, encephalitis, epilepsy, stroke, or multiple sclerosis) and psychiatric disorders such as schizophrenia, major depression, or mental retardation
Significant pulmonary disease predisposing to hypoxia
Immunological disorder such as clinically significant alleges, Lupus erythematosis, or scleroderma
Hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression
Organ system diseases which, in the opinion of the investigator, would impact on the primary and secondary endpoints of the trial such as dehydration (hematocrit > 48%) or hypothyroidism
4. Significant history of drug dependence or abuse (including alcohol, as defined in DSM IV or in the opinion of the investigator) within two years, or a positive urine drug screen for cocaine, heroin, or marijuana
5. HIV positive
6. Presence of Hepatitis C antibody
7. Planned elective surgery requiring general anesthesia or hospitalization for more than 1 day during the study period
8. Previous participation in any NS 2330 study
9. Use of any investigational drug or procedure within 30 days before randomization
10. Use of any drug within 14 days prior to randomization unless:
the dose of the drug and the condition being treated have been stable for at least 30 days and are expected to remain stable during the study
neither the drug nor the condition being treated is expected to interfere with the study endpoints
11. Treatment with donepezil, galantamine, rivastigmine, or tacrine, is prohibited within 6 weeks before randomization
12. Treatment with drugs that inhibit CYP 450 3A4 (see Appendix II for a list of relevant drugs
If they are needed under emergency conditions, the patient should discontinue the trial
13. Treatment with antipsychotics/neuroleptics is prohibited for 8 weeks prior to randomization (see listing Appendix II)
14. Treatment with monoamine oxidase inhibitors is prohibited for 8 weeks prior to randomization
15. Treatment with selective serotonin reuptake inhibitors is prohibited for 6 weeks prior to randomization
16. Tricyclic antidepressants and antihistamines are prohibited for 4 weeks prior to randomization

>>NCT00855868
Inclusion Criteria:
Normal subjects: mini-mental state examination (MMSE) 27-30, clinical dementia rating (CDR) 0, no symptoms of depression
Alzheimer's subjects: MMSE 18-26, CDR >= 0.5, University of Pennsylvania Alzheimer's Disease Center consensus diagnosis of probable AD, absence of abnormalities on MRI 
Exclusion Criteria:
other neurological disease
evidence of MRI abnormality
psychiatric disorder
alcohol abuse
clinically significant lab abnormalities
residence in nursing facility
participation in clinical trial with experimental medication in past 1 month

>>NCT01677754
Inclusion Criteria:
Adult patients, 50-90 years of age inclusive at time of screening
Probable Alzheimer disease, based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) / Alzheimer's Disease and Related Disorders Association (ADRDA) and DSM-IV-TR criteria
MMSE score at screening between 13 and 20, inclusive
Body mass index (BMI) between 18 and 36 kg/m2 (inclusive) at screening
Modified Hachinski Ischemia Score of <= 4
Patients with Cornell Scale for Depression in Dementia (CSDD) scores <= 13 at screening
Receiving treatment with donepezil or rivastigmine, galantamine or any of these AChEIs in combination with memantine for at least 4 months before screening, with their dose and formulation stabilized at least 3 months before screening
All formulation and dosages are allowed except donepezil 23 mg (alone or in combination)
Females of childbearing potential must have a negative pregnancy test and must agree to use effective contraception
Generally healthy and ambulatory or ambulatory-aided (i.e. walker or cane)
Have a reliable caregiver or some other identified responsible person who has frequent contact with the patient 
Exclusion Criteria:
Any neurological or psychiatric condition that may currently or during the course of the study impair cognition or functioning that is not associated with Alzheimer's disease
Background of mental retardation
Uncontrolled behavioral symptoms incompatible with compliance or evaluability
Alcohol and/or substance abuse or dependence (DSM-IV-TR) in the past 2 years, except nicotine use which is allowed
However, smokers treated with nicotine replacement therapy or bupropion are excluded
Unstable or poorly controlled hypertension as assessed by the investigator
Unstable or clinically significant cardiovascular disease that could be expected to progress, recur, or change during study period to such an extent that it could bias the assessment of the clinical or mental status of the patient
Inadequate hepatic, renal or thyroid function
Positive for hepatitis B, hepatitis C or HIV infection
Poorly controlled diabetes
Requiring nursing home care
Patients living in assisted living facilities are allowed if a reliable caregiver is available (see inclusion criteria)
Current treatment for AD other than those listed in inclusion criteria
Participation at any time in an active AD vaccine study
Participation in a passive AD immunization study less than 1 year before screening, with exceptions as per protocol
Psychotropic medication as defined by protocol